SCHEMBL20206039

SCHEMBL20206039

CCN1CC2CC(C1)C2C(=O)Nc1ccc(OC)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.49
KMT2A Q03164 7/20 0.49
MEN1 O00255 5/20 0.49
MAPT P10636 5/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 6/20 0.48
NPC1 O15118 5/20 0.48
RAB9A P51151 4/20 0.48
HTT P42858 3/20 0.48
FPR3 P25089 1/20 0.47
FPR2 P25090 1/20 0.47
RET P07949 1/20 0.46
PABPC1 P11940 4/20 0.45
NPSR1 Q6W5P4 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
S1PR2 O95136 3/20 0.43
S1PR4 O95977 3/20 0.43
S1PR1 P21453 3/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068838 0.87 ALDH1A1 (0.51) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL20070437 0.84 LMNA (0.48) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL20148071 0.84 ALDH1A1 (0.48) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL20205857 0.84 RAB9A (0.48) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL25505302 0.81 ALDH1A1 (0.45) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL22856995 0.80 RET (0.46) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL20069826 0.80 KMT2A (0.49) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL41767 0.73 KMT2A (0.58) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL29445396 0.73 KMT2A (0.58) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL9019385 0.73 RAB9A (0.57) LMNAKMT2AMEN1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 LMNA 1968/4885KMT2A 1112/4885MEN1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.